Vinorelbine, also known by the brand name Navelbine, is a chemotherapy drug that has been tested as a second-line treatment for mesothelioma, both as a single agent and in combination with other drugs such as cisplatin or gemcitabine.
Vinorelbine belongs to a family of chemotherapy drugs known as vinca alkaloids, which were initially created from extracts of the periwinkle plant. The antitumor effects of this drug were discovered in 1959.
Vinorelbine is classified as an antineoplastic agent. It binds to microtubular proteins in cells. Microtubules are needed for cell reproduction, so damage to the microtubules by vinorelbine prevents cancer cells from reproducing and leads to their self-destruction.
Vinorelbine is typically administered in cycles of six weekly intravenous (IV) injections, though this varies based on the patient’s health factors and whether vinorelbine is combined with another chemotherapy drug.
Get help connecting with a top mesothelioma doctor specialized with vinorelbine in mesothelioma treatment.Get Help Now
Vinorelbine regimens are not as effective at extending survival as the standard pemetrexed and cisplatin treatment for mesothelioma. However, because vinorelbine has shown some effectiveness and has relatively low toxicity, doctors have continued to explore its value as a palliative or second-line therapy.
A 2017 review of second-line chemotherapy treatment for mesothelioma suggests even though international guidelines include vinorelbine as a suggested drug, the research evidence supporting its use is inconclusive.
In 2014, the Wales Cancer Trials Unit began a phase II clinical trial to further study the effectiveness of vinorelbine as a second-line treatment. The researchers also aim to determine whether the BRCA1 gene is required for vinorelbine to cause cancer-cell death.
Daniel King joined Asbestos.com in 2017. He comes from a military family and attended high school on a military base. He feels a close connection to veterans, military families and the many hardships they face. As an investigative writer with interests in mesothelioma research and environmental issues, he seeks to educate others about the dangers of asbestos exposure to protect them from the deadly carcinogen linked to asbestos-related conditions. Daniel also holds several certificates in health writing from the Centers for Disease Control and Prevention. Read More